Global Neuroblastoma Treatment Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
The Neuroblastoma Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuroblastoma Treatment Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Neuroblastoma Treatment Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cyclophosphamide segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuroblastoma Treatment Drugs include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, and Baxter Healthcare, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuroblastoma Treatment Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Neuroblastoma Treatment Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroblastoma Treatment Drugs, with price, sales, revenue and global market share of Neuroblastoma Treatment Drugs from 2019 to 2022.
Chapter 3, the Neuroblastoma Treatment Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Treatment Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuroblastoma Treatment Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuroblastoma Treatment Drugs.
Chapter 13, 14, and 15, to describe Neuroblastoma Treatment Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neuroblastoma Treatment Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Neuroblastoma Treatment Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Cyclophosphamide segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Neuroblastoma Treatment Drugs include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, and Baxter Healthcare, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neuroblastoma Treatment Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- Cyclophosphamide
- Dinutuximab
- Naxitamab
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Other
- Hospital
- Clinic
- Other
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Neuroblastoma Treatment Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroblastoma Treatment Drugs, with price, sales, revenue and global market share of Neuroblastoma Treatment Drugs from 2019 to 2022.
Chapter 3, the Neuroblastoma Treatment Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Treatment Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Neuroblastoma Treatment Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuroblastoma Treatment Drugs.
Chapter 13, 14, and 15, to describe Neuroblastoma Treatment Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Neuroblastoma Treatment Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroblastoma Treatment Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cyclophosphamide
1.2.3 Dinutuximab
1.2.4 Naxitamab
1.2.5 Doxorubicin Hydrochloride
1.2.6 Vincristine Sulfate
1.2.7 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroblastoma Treatment Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Treatment Drugs Market Size & Forecast
1.4.1 Global Neuroblastoma Treatment Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuroblastoma Treatment Drugs Sales in Volume (2017-2028)
1.4.3 Global Neuroblastoma Treatment Drugs Price (2017-2028)
1.5 Global Neuroblastoma Treatment Drugs Production Capacity Analysis
1.5.1 Global Neuroblastoma Treatment Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neuroblastoma Treatment Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroblastoma Treatment Drugs Market Drivers
1.6.2 Neuroblastoma Treatment Drugs Market Restraints
1.6.3 Neuroblastoma Treatment Drugs Trends Analysis
2 MANUFACTURERS PROFILES
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Neuroblastoma Treatment Drugs Product and Services
2.1.4 United Therapeutics Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
2.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
2.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
2.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Neuroblastoma Treatment Drugs Product and Services
2.7.4 Pfizer Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 NEUROBLASTOMA TREATMENT DRUGS BREAKDOWN DATA BY MANUFACTURER
3.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuroblastoma Treatment Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2021
3.5 Global Neuroblastoma Treatment Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuroblastoma Treatment Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Neuroblastoma Treatment Drugs Market Size by Region
4.1.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neuroblastoma Treatment Drugs Revenue by Region (2017-2028)
4.2 North America Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.3 Europe Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.5 South America Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neuroblastoma Treatment Drugs Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neuroblastoma Treatment Drugs Revenue by Type (2017-2028)
5.3 Global Neuroblastoma Treatment Drugs Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neuroblastoma Treatment Drugs Revenue by Application (2017-2028)
6.3 Global Neuroblastoma Treatment Drugs Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
7.2 North America Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
7.3 North America Neuroblastoma Treatment Drugs Market Size by Country
7.3.1 North America Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
8.2 Europe Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
8.3 Europe Neuroblastoma Treatment Drugs Market Size by Country
8.3.1 Europe Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neuroblastoma Treatment Drugs Market Size by Region
9.3.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuroblastoma Treatment Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
10.2 South America Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
10.3 South America Neuroblastoma Treatment Drugs Market Size by Country
10.3.1 South America Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neuroblastoma Treatment Drugs Market Size by Country
11.3.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Neuroblastoma Treatment Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuroblastoma Treatment Drugs
12.3 Neuroblastoma Treatment Drugs Production Process
12.4 Neuroblastoma Treatment Drugs Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuroblastoma Treatment Drugs Typical Distributors
13.3 Neuroblastoma Treatment Drugs Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
1.1 Neuroblastoma Treatment Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroblastoma Treatment Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Cyclophosphamide
1.2.3 Dinutuximab
1.2.4 Naxitamab
1.2.5 Doxorubicin Hydrochloride
1.2.6 Vincristine Sulfate
1.2.7 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroblastoma Treatment Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Treatment Drugs Market Size & Forecast
1.4.1 Global Neuroblastoma Treatment Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Neuroblastoma Treatment Drugs Sales in Volume (2017-2028)
1.4.3 Global Neuroblastoma Treatment Drugs Price (2017-2028)
1.5 Global Neuroblastoma Treatment Drugs Production Capacity Analysis
1.5.1 Global Neuroblastoma Treatment Drugs Total Production Capacity (2017-2028)
1.5.2 Global Neuroblastoma Treatment Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroblastoma Treatment Drugs Market Drivers
1.6.2 Neuroblastoma Treatment Drugs Market Restraints
1.6.3 Neuroblastoma Treatment Drugs Trends Analysis
2 MANUFACTURERS PROFILES
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Neuroblastoma Treatment Drugs Product and Services
2.1.4 United Therapeutics Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
2.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
2.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
2.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Neuroblastoma Treatment Drugs Product and Services
2.7.4 Pfizer Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
2.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 NEUROBLASTOMA TREATMENT DRUGS BREAKDOWN DATA BY MANUFACTURER
3.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Neuroblastoma Treatment Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2021
3.5 Global Neuroblastoma Treatment Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Neuroblastoma Treatment Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 MARKET ANALYSIS BY REGION
4.1 Global Neuroblastoma Treatment Drugs Market Size by Region
4.1.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Neuroblastoma Treatment Drugs Revenue by Region (2017-2028)
4.2 North America Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.3 Europe Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.4 Asia-Pacific Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.5 South America Neuroblastoma Treatment Drugs Revenue (2017-2028)
4.6 Middle East and Africa Neuroblastoma Treatment Drugs Revenue (2017-2028)
5 MARKET SEGMENT BY TYPE
5.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Type (2017-2028)
5.2 Global Neuroblastoma Treatment Drugs Revenue by Type (2017-2028)
5.3 Global Neuroblastoma Treatment Drugs Price by Type (2017-2028)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neuroblastoma Treatment Drugs Sales in Volume by Application (2017-2028)
6.2 Global Neuroblastoma Treatment Drugs Revenue by Application (2017-2028)
6.3 Global Neuroblastoma Treatment Drugs Price by Application (2017-2028)
7 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 North America Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
7.2 North America Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
7.3 North America Neuroblastoma Treatment Drugs Market Size by Country
7.3.1 North America Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
8.1 Europe Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
8.2 Europe Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
8.3 Europe Neuroblastoma Treatment Drugs Market Size by Country
8.3.1 Europe Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
9.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Neuroblastoma Treatment Drugs Market Size by Region
9.3.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Neuroblastoma Treatment Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 SOUTH AMERICA BY REGION, BY TYPE, AND BY APPLICATION
10.1 South America Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
10.2 South America Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
10.3 South America Neuroblastoma Treatment Drugs Market Size by Country
10.3.1 South America Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
11.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Neuroblastoma Treatment Drugs Market Size by Country
11.3.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 RAW MATERIAL AND INDUSTRY CHAIN
12.1 Raw Material of Neuroblastoma Treatment Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Neuroblastoma Treatment Drugs
12.3 Neuroblastoma Treatment Drugs Production Process
12.4 Neuroblastoma Treatment Drugs Industrial Chain
13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Neuroblastoma Treatment Drugs Typical Distributors
13.3 Neuroblastoma Treatment Drugs Typical Customers
14 RESEARCH FINDINGS AND CONCLUSION
15 APPENDIX
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
LIST OF TABLES
Table 1. Global Neuroblastoma Treatment Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuroblastoma Treatment Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. United Therapeutics Major Business
Table 5. United Therapeutics Neuroblastoma Treatment Drugs Product and Services
Table 6. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
Table 8. Y-mAbs Therapeutics Major Business
Table 9. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
Table 10. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. EUSA Pharma Basic Information, Manufacturing Base and Competitors
Table 12. EUSA Pharma Major Business
Table 13. EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
Table 14. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. ANI Pharmaceuticals Major Business
Table 17. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 18. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 20. Baxter Healthcare Major Business
Table 21. Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
Table 22. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Ingenus Pharmaceuticals Major Business
Table 25. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 26. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Pfizer Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer Major Business
Table 29. Pfizer Neuroblastoma Treatment Drugs Product and Services
Table 30. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Hikma Pharmaceuticals Major Business
Table 33. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 34. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 36. Teva Pharmaceuticals Major Business
Table 37. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 38. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Neuroblastoma Treatment Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 40. Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Neuroblastoma Treatment Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Neuroblastoma Treatment Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and Neuroblastoma Treatment Drugs Production Site of Key Manufacturer
Table 44. Neuroblastoma Treatment Drugs New Entrant and Capacity Expansion Plans
Table 45. Neuroblastoma Treatment Drugs Mergers & Acquisitions in the Past Five Years
Table 46. Global Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
Table 47. Global Neuroblastoma Treatment Drugs Sales by Region (2023-2028) & (K Units)
Table 48. Global Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Neuroblastoma Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 51. Global Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 52. Global Neuroblastoma Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Neuroblastoma Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Neuroblastoma Treatment Drugs Price by Type (2017-2022) & (US$/Unit)
Table 55. Global Neuroblastoma Treatment Drugs Price by Type (2023-2028) & (US$/Unit)
Table 56. Global Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 57. Global Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 58. Global Neuroblastoma Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Neuroblastoma Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Neuroblastoma Treatment Drugs Price by Application (2017-2022) & (US$/Unit)
Table 61. Global Neuroblastoma Treatment Drugs Price by Application (2023-2028) & (US$/Unit)
Table 62. North America Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
Table 63. North America Neuroblastoma Treatment Drugs Sales by Country (2023-2028) & (K Units)
Table 64. North America Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Neuroblastoma Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 67. North America Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 68. North America Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 69. North America Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
Table 71. Europe Neuroblastoma Treatment Drugs Sales by Country (2023-2028) & (K Units)
Table 72. Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Neuroblastoma Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 75. Europe Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 76. Europe Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Europe Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
Table 79. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Region (2023-2028) & (K Units)
Table 80. Asia-Pacific Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Neuroblastoma Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 83. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 84. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 85. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 86. South America Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
Table 87. South America Neuroblastoma Treatment Drugs Sales by Country (2023-2028) & (K Units)
Table 88. South America Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Neuroblastoma Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 91. South America Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 92. South America Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 93. South America Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 94. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
Table 95. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Region (2023-2028) & (K Units)
Table 96. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 99. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 100. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 101. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 102. Neuroblastoma Treatment Drugs Raw Material
Table 103. Key Manufacturers of Neuroblastoma Treatment Drugs Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Neuroblastoma Treatment Drugs Typical Distributors
Table 107. Neuroblastoma Treatment Drugs Typical Customers
Table 1. Global Neuroblastoma Treatment Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Neuroblastoma Treatment Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. United Therapeutics Major Business
Table 5. United Therapeutics Neuroblastoma Treatment Drugs Product and Services
Table 6. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
Table 8. Y-mAbs Therapeutics Major Business
Table 9. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
Table 10. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. EUSA Pharma Basic Information, Manufacturing Base and Competitors
Table 12. EUSA Pharma Major Business
Table 13. EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
Table 14. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 16. ANI Pharmaceuticals Major Business
Table 17. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 18. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 20. Baxter Healthcare Major Business
Table 21. Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
Table 22. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Ingenus Pharmaceuticals Major Business
Table 25. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 26. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Pfizer Basic Information, Manufacturing Base and Competitors
Table 28. Pfizer Major Business
Table 29. Pfizer Neuroblastoma Treatment Drugs Product and Services
Table 30. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 32. Hikma Pharmaceuticals Major Business
Table 33. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 34. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 36. Teva Pharmaceuticals Major Business
Table 37. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
Table 38. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Global Neuroblastoma Treatment Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 40. Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 41. Market Position of Manufacturers in Neuroblastoma Treatment Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 42. Global Neuroblastoma Treatment Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 43. Head Office and Neuroblastoma Treatment Drugs Production Site of Key Manufacturer
Table 44. Neuroblastoma Treatment Drugs New Entrant and Capacity Expansion Plans
Table 45. Neuroblastoma Treatment Drugs Mergers & Acquisitions in the Past Five Years
Table 46. Global Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
Table 47. Global Neuroblastoma Treatment Drugs Sales by Region (2023-2028) & (K Units)
Table 48. Global Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 49. Global Neuroblastoma Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 50. Global Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 51. Global Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 52. Global Neuroblastoma Treatment Drugs Revenue by Type (2017-2022) & (USD Million)
Table 53. Global Neuroblastoma Treatment Drugs Revenue by Type (2023-2028) & (USD Million)
Table 54. Global Neuroblastoma Treatment Drugs Price by Type (2017-2022) & (US$/Unit)
Table 55. Global Neuroblastoma Treatment Drugs Price by Type (2023-2028) & (US$/Unit)
Table 56. Global Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 57. Global Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 58. Global Neuroblastoma Treatment Drugs Revenue by Application (2017-2022) & (USD Million)
Table 59. Global Neuroblastoma Treatment Drugs Revenue by Application (2023-2028) & (USD Million)
Table 60. Global Neuroblastoma Treatment Drugs Price by Application (2017-2022) & (US$/Unit)
Table 61. Global Neuroblastoma Treatment Drugs Price by Application (2023-2028) & (US$/Unit)
Table 62. North America Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
Table 63. North America Neuroblastoma Treatment Drugs Sales by Country (2023-2028) & (K Units)
Table 64. North America Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 65. North America Neuroblastoma Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 66. North America Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 67. North America Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 68. North America Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 69. North America Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
Table 71. Europe Neuroblastoma Treatment Drugs Sales by Country (2023-2028) & (K Units)
Table 72. Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 73. Europe Neuroblastoma Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 74. Europe Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 75. Europe Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 76. Europe Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Europe Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
Table 79. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Region (2023-2028) & (K Units)
Table 80. Asia-Pacific Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 81. Asia-Pacific Neuroblastoma Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 82. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 83. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 84. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 85. Asia-Pacific Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 86. South America Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
Table 87. South America Neuroblastoma Treatment Drugs Sales by Country (2023-2028) & (K Units)
Table 88. South America Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & (USD Million)
Table 89. South America Neuroblastoma Treatment Drugs Revenue by Country (2023-2028) & (USD Million)
Table 90. South America Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 91. South America Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 92. South America Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 93. South America Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 94. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
Table 95. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Region (2023-2028) & (K Units)
Table 96. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & (USD Million)
Table 97. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Region (2023-2028) & (USD Million)
Table 98. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
Table 99. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2023-2028) & (K Units)
Table 100. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
Table 101. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2023-2028) & (K Units)
Table 102. Neuroblastoma Treatment Drugs Raw Material
Table 103. Key Manufacturers of Neuroblastoma Treatment Drugs Raw Materials
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Neuroblastoma Treatment Drugs Typical Distributors
Table 107. Neuroblastoma Treatment Drugs Typical Customers
LIST OF FIGURES
Figure 1. Neuroblastoma Treatment Drugs Picture
Figure 2. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type in 2021
Figure 3. Cyclophosphamide
Figure 4. Dinutuximab
Figure 5. Naxitamab
Figure 6. Doxorubicin Hydrochloride
Figure 7. Vincristine Sulfate
Figure 8. Other
Figure 9. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Neuroblastoma Treatment Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 14. Global Neuroblastoma Treatment Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Neuroblastoma Treatment Drugs Sales (2017-2028) & (K Units)
Figure 16. Global Neuroblastoma Treatment Drugs Price (2017-2028) & (US$/Unit)
Figure 17. Global Neuroblastoma Treatment Drugs Production Capacity (2017-2028) & (K Units)
Figure 18. Global Neuroblastoma Treatment Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Neuroblastoma Treatment Drugs Market Drivers
Figure 20. Neuroblastoma Treatment Drugs Market Restraints
Figure 21. Neuroblastoma Treatment Drugs Market Trends
Figure 22. Global Neuroblastoma Treatment Drugs Sales Market Share by Manufacturer in 2021
Figure 23. Global Neuroblastoma Treatment Drugs Revenue Market Share by Manufacturer in 2021
Figure 24. Neuroblastoma Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Neuroblastoma Treatment Drugs Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Neuroblastoma Treatment Drugs Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 28. Global Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 29. North America Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Europe Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 32. South America Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 34. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 35. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2028)
Figure 36. Global Neuroblastoma Treatment Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 37. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 38. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2017-2028)
Figure 39. Global Neuroblastoma Treatment Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 40. North America Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 41. North America Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 42. North America Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2028)
Figure 43. North America Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 44. United States Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 48. Europe Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 49. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2028)
Figure 50. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 51. Germany Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 60. China Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 67. South America Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 68. South America Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2028)
Figure 69. South America Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 76. Turkey Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2021
Figure 81. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
Figure 82. Neuroblastoma Treatment Drugs Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Neuroblastoma Treatment Drugs Picture
Figure 2. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type in 2021
Figure 3. Cyclophosphamide
Figure 4. Dinutuximab
Figure 5. Naxitamab
Figure 6. Doxorubicin Hydrochloride
Figure 7. Vincristine Sulfate
Figure 8. Other
Figure 9. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application in 2021
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Neuroblastoma Treatment Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 14. Global Neuroblastoma Treatment Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 15. Global Neuroblastoma Treatment Drugs Sales (2017-2028) & (K Units)
Figure 16. Global Neuroblastoma Treatment Drugs Price (2017-2028) & (US$/Unit)
Figure 17. Global Neuroblastoma Treatment Drugs Production Capacity (2017-2028) & (K Units)
Figure 18. Global Neuroblastoma Treatment Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 19. Neuroblastoma Treatment Drugs Market Drivers
Figure 20. Neuroblastoma Treatment Drugs Market Restraints
Figure 21. Neuroblastoma Treatment Drugs Market Trends
Figure 22. Global Neuroblastoma Treatment Drugs Sales Market Share by Manufacturer in 2021
Figure 23. Global Neuroblastoma Treatment Drugs Revenue Market Share by Manufacturer in 2021
Figure 24. Neuroblastoma Treatment Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 25. Top 3 Neuroblastoma Treatment Drugs Manufacturer (Revenue) Market Share in 2021
Figure 26. Top 6 Neuroblastoma Treatment Drugs Manufacturer (Revenue) Market Share in 2021
Figure 27. Global Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 28. Global Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 29. North America Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Europe Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Asia-Pacific Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 32. South America Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 33. Middle East & Africa Neuroblastoma Treatment Drugs Revenue (2017-2028) & (USD Million)
Figure 34. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 35. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2028)
Figure 36. Global Neuroblastoma Treatment Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 37. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 38. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2017-2028)
Figure 39. Global Neuroblastoma Treatment Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 40. North America Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 41. North America Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 42. North America Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2028)
Figure 43. North America Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 44. United States Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 48. Europe Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 49. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2028)
Figure 50. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 51. Germany Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 59. Asia-Pacific Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 60. China Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Korea Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 67. South America Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 68. South America Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2028)
Figure 69. South America Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2028)
Figure 73. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2028)
Figure 74. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2028)
Figure 75. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2028)
Figure 76. Turkey Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Egypt Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. South Africa Neuroblastoma Treatment Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2021
Figure 81. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
Figure 82. Neuroblastoma Treatment Drugs Industrial Chain
Figure 83. Sales Channel: Direct Channel vs Indirect Channel
Figure 84. Methodology
Figure 85. Research Process and Data Source
